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Koen Van Laere, MD, PhD, DSc; Annelies Vanhee, MD; Jolien Verschueren, MD; Liesbeth De Coster, MD;
An Driesen, MD; Patrick Dupont, PhD; Wim Robberecht, MD, PhD; Philip Van Damme, MD, PhD
IMPORTANCE Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder primarily
affecting themotor system, with extramotor involvement to a variable extent. Biomarkers for
early differential diagnosis and prognosis are needed. An autosomal dominant
hexanucleotide (GGGGCC) expansion in the noncoding region of the chromosome 9 open
reading frame 72 (C9orf72) gene is themost frequent genetic cause of ALS, but its metabolic
pattern has not been studied systematically.
OBJECTIVES To evaluate the use of 18fluorodeoxyglucose–positron-emission tomography as a
marker of ALS pathology and investigate whether a specific metabolic signature is present in
patients with C9orf72mutations.
DESIGN, SETTING, AND PARTICIPANTS In total, 81 patients with a suspected diagnosis of ALS at
University Hospital Leuven were prospectively investigated. All underwent detailed
neurological examination and electrodiagnostic and genetic testing for themajor known
genetic causes of ALS (C9orf72, SOD1, TARDBP, and FUS). A diagnosis of ALS wasmade in 70
of 81 patients. Of these, 11 were C9orf72 positive and 59were C9orf72 negative. In 7 patients,
the diagnosis of primary lateral sclerosis was made; 4 patients had progressive muscular
atrophy. A screened healthy control population was used for comparison.
MAIN OUTCOMES ANDMEASURES Positron-emission tomographic data were spatially
normalized and analyzed using a predefined volume of interest and a voxel-based analysis
(SPM8). Discriminant analysis was done both volume of interest based and voxel based using
a support vector machine approach.
RESULTS Compared with control participants, 18fluorodeoxyglucose–positron-emission
tomography showed perirolandic and variable prefrontal hypometabolism in most patients.
Patients with primary lateral sclerosis showed a similar pattern. Patients with
C9orf72-positive ALS had discrete relative hypometabolism in the thalamus and posterior
cingulate compared with those with C9orf72-negative ALS. A posteriori-corrected
discriminant analysis was able to correctly classify 95% of ALS cases and 71% of primary
lateral sclerosis cases. Prefrontal hypometabolismwas associated with reduced clinical
functioning (ALS Functional Rating Scale). Extensive hypometabolism in the prefrontal or
anterior temporal areas was present in 10% of patients and associated with significantly
shorter survival as an independent factor (n = 63, P < .001). Patients who were C9orf72
positive did not differ in survival compared with those whowere C9orf72 negative.
CONCLUSIONS AND RELEVANCE 18Fluorodeoxyglucose–positron-emission tomography is a
useful early diagnostic and prognostic marker for ALS. Amyotrophic lateral sclerosis that is
positive for C9orf72 is characterized by only mild cerebral metabolic differences that show no
prognostic difference.
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M otor neuron disorders (MNDs) comprise a group ofdisorders involvingpreferentialdamagetouppermo-tor neurons (UMNs) and/or lower motor neurons
(LMNs).1,2 Inadulthood, theclinical spectrumofMNDs iswide,
ranging from simultaneous involvement of UMNs and LMNs
(classic amyotrophic lateral sclerosis [ALS], about 90% of all
MND cases), a pure UMN syndrome (primary lateral sclerosis
[PLS]), and an isolated LMN involvement (progressive mus-
cular atrophy [PMA]).1 It has not been settledwhether the lat-
ter 2 are entities fully separated from ALS because a consid-
erable number of patientswith PLS and PMAprogress to ALS.
A diagnosis of ALS predominantly relies on the interpre-
tation of clinical symptoms and signs, with the use of ancil-
lary tests to exclude other causes.1-3 Currently, the revised El
Escorial andAwaji-Shima diagnostic criteria are used, the lat-
ter beingmore sensitive for early disease assessment.4 Upper
motorneuron symptomsare spasticity, hyperreflexia, and the
Babinski sign,whereasLMNloss leads tomuscleweaknessand
wasting with fasciculations. Depending on symptom onset,
clinical presentations of ALSmay be separated into bulbar or
spinal-onset disease.
It is nowrecognized thatALSandPLSare characterizedby
significant extramotor cerebral pathology that, to a variable
extent, overlapswith the clinicopathological features of fron-
totemporal lobar degeneration (FTLD),5 and cognitive de-
clinemay range frommild abnormalities tomanifest FTLD in
about 5% to 15% of cases.6
Although most MND patients are sporadic, approxi-
mately10%haveapositive familyhistory.6Previously, themost
prevalent and best-knownmutation was in the Cu/Zn super-
oxidedismutase 1gene (SOD1),whereasothergenes that cause
autosomal-dominantALS (such asTARDBP,FUS,VAPB,ANG,
OPTN, UBQLN2, and ATXN2) only accounted for a small per-
centage of cases. In 2011, a new gene defect was identified,
namely, a massively expanded GGGGCC hexanucleotide re-
peat in a noncoding region of the chromosome 9 open read-
ing frame 72 (C9orf72) gene.7,8 Phenotypically, patients with
the expansion have a younger age at onset, shortened sur-
vival, increased rates of cognitive and behavioral impair-
ment, and a strong family history of neurodegenerative
disease.9-16 This mutation is currently recognized as a major
genetic cause of ALS and FTLD, responsible for up to 40% of
familial ALS, 5% to 10% of sporadic ALS, about 20% of famil-
ial FTLD, and 5% of sporadic FTLD.15,17-20
At theneuropathological level,most formsofALSarechar-
acterized by the presence of inclusions in degenerating mo-
tor neurons staining positively for ubiquitin and TAR DNA-
bindingprotein43.Whereas thepresenceofLMNdegeneration
can be confirmed by electrodiagnostic testing, there is no
widely accepted biomarker for UMN involvement.21 How-
ever, reliable objective biomarkers are critical for the early di-
agnosis,monitoringofdiseaseprogression,prognosis, andpa-
tient stratification for clinical trials.
Whereas magnetic resonance imaging (MRI) of the brain
and spinal cord remains a most useful neuroimaging tech-
nique in ALS, this ismainly to exclude syndromes thatmimic
ALS.6Voxel-basedmorphometry reveals regional atrophy, and
magnetic resonancespectroscopyanddiffusion-tensorMRIcan
detect corticospinal lesions. However, because of their rela-
tive lackof sensitivityandspecificity, these techniquesarecur-
rently inadequate for use as diagnostic tools in individual
patients.1,22,23
Early 18fluorodeoxyglucose (FDG)–positron-emission to-
mography (PET) imaging studies conducted in limited num-
bers of patients (n < 20) and dating back 25 years have shown
that patients with ALS have decreased glucose uptake that is
more extended than motor areas.24-27 Frontal hypometabo-
lismhasbeenassociatedwithneuropsychological deficits,27,28
especially to disturbances of word fluency.26,29 Detecting ex-
tramotor involvement is important because comorbid cogni-
tive dysfunctionhas been associatedwith functional decline,
shortened survival, and poor compliance with life-
prolonging interventions.30,31
Voxel-basedapproacheshave ledtoamoredetailed,group-
based characterization of the disorder spectrum. In a study in
32 patients, the pattern of UMN (bulbar) and LMN (spinal)
onset could be differentiated by FDG-PET.32 To our knowl-
edge, the individual discrimination capacity of FDG-PET as
an aid in early and differential diagnosis in MND has not
been studied.
The aimof this studywas 3-fold: first, to evaluate glucose
metabolismina largegroupofpatientswithALSandthosewith
PLS, in comparison to age-matched healthy control partici-
pants, to assess the diagnostic value of voxel-based classifi-
cation. Second, our goalwas to study themetabolic impact of
theC9orf72mutation inpatientswithALS.Andthird,weaimed
to relate survival ofpatientswithALSassociatedwith thepres-
ence of frontotemporal hypometabolism.
Methods
Patients (n = 81) were consecutively recruited from referrals
made to the neuromuscular clinic at the University Hospital
Leuven (Leuven, Belgium) between January 2011 and Janu-
ary 2013. None of the patients had a history of other neuro-
logical disorders. All underwent full neurological evaluation
and electrodiagnostic testing as part of their clinical workup
byanexperiencedspecialist inneuromusculardisorders (P.V.D.
or W.R.). Both the revised El Escorial and Awaji-Shima crite-
ria were applied.4 All patients underwent FDG-PET planned
at the initial visit. All patients had undergone a routine MRI
scan of the brain. All patients underwent genetic testing for
C9orf72, SOD1, TARDBP, and FUS at the time of diagnosis. A
C9orf72 repeat expansion was checked for by repeat-primed
polymerase chain reaction, andmutations in SOD1, TARDBP,
and FUS were as sought for by Sanger sequencing, as previ-
ously described.15,33-35
Onset of the diseasewas determined by the patient’s rec-
ollection of themonth inwhich the first symptoms occurred.
Noneof the patients showedevidence of respiratory compro-
mise or nutritional abnormalities, such as dehydration or ke-
tosis, at the time of the FDG-PET scan. The functional status
of thepatients near the timeof PET imagingwas scoredby the
revisedversionof theALSFunctionalRatingScale (FRS) inmost
patients. Also, forced vital capacity as a marker of lung func-
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tion was scored (Table 1). Control participants were part of a
prospective study in healthy volunteers aged 50 to 80 years
acquired over the sameperiodon the sameequipment. Inclu-
sion and exclusion details for this substudy are given in eAp-
pendix 1 in Supplement.
Thestudywasapprovedby the localuniversityethics com-
mitteeandwritten informedconsentwasgivenbypatientsand
control participants, according to theDeclaration ofHelsinki.
Positron-emissiontomographyacquisition,processing,andsta-
tisticsareprovided ineAppendix1 inSupplement.Patientchar-
acteristics aregiven ineAppendix2 inSupplementandTable 1.
Results
Categorical Differences of ALS vs Control Cases
On an individual visual level, as diagnosed in clinical routine
using surfaceprojections and z-maps, FDG-PET showedareas
ofhypometabolism invirtuallyall individualpatientswithALS
and thosewith PLS,with variable intensity ranging fromvery
mild to severe. Themost common regionswith hypometabo-
lismclinically reportedwere theperirolandic and frontal brain
regions.
Voxel-based group analysis showed that, compared with
healthy control participants, patients with ALS had signifi-
cant, symmetrical hypometabolism in the prefrontal, lateral
frontal, and premotor cortex. Patients with ALS showed also
clusters of relative hypermetabolism in the cerebellum, oc-
cipital cortex, upper brain stem, andmedial temporal cortex,
encompassing thehippocampus andamygdala (Figure 1Aand
eTable 1 in Supplement for cluster statistics and locations). In
3 of 4 patients diagnosed as having PMA, a similar pattern of
hypometabolismwas seen.OnepatientwithPMA,with amu-
tation in SOD1, had a visually normal FDG-PET.
Categorical Differences of C9orf72Negative vs C9orf72
Positive
Therewereno significantdifferences inpatientswithC9orf72-
positivevsC9orf72-negativeALS intimeofdiseaseonset toPET,
bulbar vs spinal onset, forcedvital capacitymeasurements, or
ALS-FRS values. Patients with C9orf72-positive ALS showed
a similar pattern of hypometabolism compared with control
participants, slightlymorepronouncedbilaterally in the thala-
mus and posterior cingulate and precuneus (Figure 1B and
eTable 1 in Supplement). These resultswere confirmedbyvol-
ume of interest (VOI)–based analysis of variance, with a dif-
ference for theposterior cingulate of 4.0% (P = .003, post hoc–
corrected univariate analysis of variance) (eFigure 1 in
Supplement).
Direct comparison of C9orf72-positive ALS vs C9orf72-
negative ALS showed no differences at the preset thresholds.
Exploratively, at a less stringent threshold of significance, pa-
tientswithC9orf72-positive ALS showed relatively lowerme-
tabolism in the anterior and posterior cingulate, posterior
thalami, right lateral frontal cortex, and right temporopari-
etal junction (Figure 1C and eTable 1 in Supplement).
Categorical Differences of ALS vs PLS
Patients with PLS also showed symmetrically decreased me-
tabolism bilaterally in the prefrontal cortex, anterior cingu-
late, pericentral cortex, and thalamus (Figure 2Aand eTable 2
in Supplement). Relative hypermetabolism was also present
in the cerebellum, occipital cortex, and left lateral temporal
cortex.
Table 1. Demographic and Clinical Characteristics of the Study Participants
Characteristic
Mean (SD)
Control
ALS
PLS PMAAll C9orf72 Negative C9orf72 Positive
No. 20 70 59 11 7 4
Sex, No.
Male 12 44 37 7 2 3
Female 8 26 22 4 5 1
Age at onset, y 60.4 (12.6) 60.8 (13.1) 58.5 (9.4) 52.4 (13.1) 66.2 (5.3)
Diagnostic delay, mo 12.6 (10.1) 12.7 (10.3) 12.5 (9.8) 47.1 (52.7)a 12.5 (5.3)
Age at PET, y 62.4 (6.4) 62.1 (12.5) 62.6 (13.0) 61.2 (9.2) 57.5 (12.9) 67.5 (5.6)
Time onset to PET, mo 15.2 (10.7) 15.0 (10.6) 13.8 (10.2) 52.3 (52.1)a 12.5 (5.7)
Time diagnosis to PET, mo 2.1 (3.5) 2.3 (3.8) 1.3 (1.0) 5.3 (15.1) 0.1 (0.6)
Awaji-Shima diagnostic
category, definite/prob-
able/
possible, No.
32/29/9 21/29/9 11/0/0
Onset type, S/B 48/21 40/18 8/3 6/1 3/1
FVC, % 93.9 (24.0) 93.3 (21.6) 96.8 (35.0) 119.0 (9.3)a 97.7 (35.0)
ALS FRS-R score 36.3 (7.2) [n = 46] 36.2 (6.1)[n = 40] 32.5 (12.7) [n = 6] 39.2 (6.9)[n = 4] 41.2 (3.4)[n = 4]
Abbreviations: ALS, amyotrophic lateral sclerosis; B, bulbar; FRS-R, Functional
Rating Scale–Revised; FVC, forced vital capacity; PET, positron-emission
tomography; PLS, primary lateral sclerosis; PMA, progressive muscular atrophy;
S, spinal.
a P < .05 compared with all ALS.
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Direct comparison between PLS and ALS on a group
level showed more severe metabolic involvement of
the prefrontal cortex and posterior cingulate in ALS
(Pheight < .005; kE = 200; Figure 2B and eTable 1 in Supple-
ment for cluster locations and statistics). The inverse con-
trast showed lower metabolism in the primary sensorimotor
cortex in PLS in bilateral clusters, which was only significant
after small-volume correction (PFDR < .05; T statistic, 3.99
left and 3.76 right) based on the a priori spatial restriction of
known primary motor cortex involvement in MND (data not
shown in Figure 2B).
Discriminant Analysis
VOI Based
To evaluate the use of FDG-PET to discriminate between dif-
ferent forms of motor neuron degeneration, a discriminant
analysiswasperformed. In total, 88VOI regionswereused for
discriminant analysis between control participants, patients
with ALS, and patients with PLS. Using equal a priori prob-
abilities as the most conservative estimation, the classifica-
tionmatrixafter leave-one-outcross-validation (Table2) shows
an overall classification accuracy of 89.7% (91.8% without
cross-validation). The most discriminating regions were the
prefrontal cortex, thalamus, posterior cingulate, and anterior
cingulate (Figure 3). In total, 10 of 97 individuals were mis-
classified: 4 ALS cases as control participants, 4 ALS cases as
PLS cases, and 2 PLS cases as ALS cases. eFigure 2 in Supple-
ment shows the canonical discriminant function values with
classification plot.
When including patients with PMA in the analysis, cross-
validatedclassificationaccuracydropped to62.4%,as the cen-
Figure 2. Relative GlucoseMetabolism in Primary Lateral Sclerosis (PLS)
vs Controls and vs Amyotrophic Lateral Sclerosis (ALS)
A B
A, Surface and interhemispheric projections of areas with relative
hypometabolism (red) and hypermetabolism (blue) for patients with PLS vs
healthy control cases (Pheight < .001). B, Patients with PLS vs those with ALS
(Pheight < .005).
Figure 1. Relative GlucoseMetabolism in C9orf72-Positive and C9orf72-Negative PatientsWith Amyotrophic Lateral Sclerosis (ALS) and Control Cases
A B C
A, Surface and interhemispheric projections of areas with relative
hypometabolism (red) and hypermetabolism (blue) for patients with ALS vs
healthy control cases (Pheight < .001). B, Patients with C9orf72-positive ALS vs
healthy control cases (Pheight < .001). C, Patients with C9orf72-positive vs those
with C9orf72-negative ALS (Pheight < .005).
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troid of the PMA group was very close to ALS, and discrimi-
native featuresofmotor cortexand thalamicdysfunctionwere
not noted for PMA (Figure 3). However, because of the very
small PMA group, these findings have to be interpreted with
caution.
In the clinically relevant setting of only patientswithALS
vs control participants (ie, when a priori clinical information
was included), overall classification accuracywas 94.4%with
5ALS casesmisclassified as control cases.Discriminant analy-
sis could not separate C9orf72-negative and C9orf72-positive
ALS with an accuracy greater than 60%, confirming the high
overlap between both groups of patients.
Support VectorMachine Analysis
To further refine the discriminating regions in patients with
ALSandthosewithPLS,a supportvectormachine (SVM)analy-
siswasperformed.The classifier imagebetweenALSandcon-
trol participants is shown inFigure4A,and the individual SVM
distances are given in Figure 4B. Themost important clusters
of discrimination by SVM were found bilateral in the thala-
mus,primarymotorcortex, striatum,prefrontaland lateralpre-
frontal cortex,andposteriorcingulate.ForALSvscontrol cases,
the leave-one-out approach had a sensitivity of 94.8, a speci-
ficityof80.0%,andanaccuracyof91.8%.Similarly, for thesub-
groupsofpatientswithC9orf72-negativeALS, sensitivity, speci-
ficity, and accuracy were 89.8%, 85.0%, and 88.6%,
respectively.ForpatientswithC9orf72-positiveALS, thesewere
90.9%, 100%, and 96.8%, respectively.
For PLS vs control cases, these values decreased to 57.1%
for sensitivity (specificity 100%). An SVMwas not able to dis-
criminatebetweenC9orf72-positive andC9orf72-negativeALS
(sensitivity 0%), in concordance with the small differences
found by voxel-based group comparison.
Survival vs Frontotemporal Metabolism
At the timeof thewritingof this article, 20of 70 (28.6%)of this
patient cohorthaddied (mean [SD] survival after symptomon-
set in these patients, 19.9 [7.1] months). For all surviving pa-
tients (50 of 70), more than 14 months of follow-up after dis-
easeonsetwasavailable (average [SD], 39.9 [16.9]months) and
48of 50 (96%)of the survivingpatientswerebeyond thepoint
of the 20-month disease duration.
In 7 of 70patients (10%), large areaswith amore than 2 SD
decreased uptake in frontal and/or anterior temporal regions
were observed. Of these, 6 of 7 patients had died after surviv-
ing amean (SD) of only 20.0 (7.0)months (Figure 5A; for clini-
cal details of these patients, see eTable 3 in Supplement). The
lower survival in the patients with ALS with severe fronto-
temporal metabolic involvement was highly significant
(P < .001). This shortened survival was not owing to the con-
tribution of C9orf72-positive patients (Figure 5B, P = .45). In
this cohort, no correlation between survival and site of onset
(P = .46)was found. After correction for other prognostic fac-
tors, such as age at onset (P = .001; hazard ratio, 1.08; 95%CI,
1.03-1.13) and forced vital capacity (P = .01; hazard ratio, 0.98;
95% CI, 0.96-0.99), the extensive hypometabolism on FDG-
PET remained significant (P = .005; HR, 4.1; 95% CI, 1.6-11.0).
The correlation between frontal hypometabolismandALS
FRS is described in eAppendix 2 and eFigure 3 in Supplement.
Discussion
Reliablediagnostic anddisease-statebiomarkersofmotorneu-
ron degenerationwould facilitate themanagement and clini-
cal trials of patients with ALS.23 Imaging techniques, espe-
cially MRI sequences, have shown their potential to track
cerebralmotor andextramotorpathology inALS.36,37 Conven-
tionalMRI findings—such as corticospinal tract hyperintensi-
ties on fluid-attenuated inversion recovery, T2-weighted, and
proton density images or a hypointense rim at the margin of
the precentral gyrus in T2-weighted images—are frequently
found inpatientswithALS, but the overlapwith control cases
is high and therefore lacking specificity.38 Voxel-based mor-
phometry and cortical thickness measurements have re-
vealed atrophy in the motor cortex and frontal involvement
in patientswith ALS. Diffusion-tensor imaging of the cortico-
spinal tract shows a significantly decreased fractional anisot-
ropy inpatientswithALS andUMNdegenerationbutdoesnot
providesufficientdiscriminatorypowerat the individual level.
Magnetic resonance spectroscopy of the motor cortex has
shownabnormally lowN-acetylaspartate levels inpatientswith
advanced ALS that is correlated with verbal fluency
deterioration,39but studies at theearly stageof thediseaseand
with an adequate follow-up are scarce.40 Also, previous FDG-
PET studies in smaller sample sizes have shown significant
group differences but have not focused yet on classification
accuracy on the level of an individual patient.24-27
Advancedclassification techniquesusingwhole-brainana-
lytic approaches have the potential to ameliorate the accu-
racy of discrimination on an individual patient level. There-
fore, in this study,weevaluated thevalueofFDG-PET ina large
prospective cohort of patientswithALS around the timeof di-
agnosisusingwhole-brain region-baseddiscriminantandSVM
tools.
To our knowledge, this study is the first to report on glu-
cose metabolic patterns on a group basis in a cohort of pa-
tientswithC9orf72-positive ALS. So far, only cases ofC9orf72
ALS with FDG-PET and 99mTc-ECD perfusion single-photon
emission computed tomographyhavebeendescribed, each in
Table 2. Stepwise Forward Discriminant Analysisa
Group % Correct Control ALS PLS
Control 100.0 20 0 0
ALS 88.6 4 64 3
PLS 71.4 0 2 5
Total 89.7 24 66 8
Abbreviations: ALS, amyotrophic
lateral sclerosis; PLS, primary lateral
sclerosis.
a Values with equal a priori
probabilities for separation between
control cases, patients with ALS,
and patients with PLS after
leave-one-out cross-validation.
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5 patients with combined ALS–frontotemporal dementia.19
Concordantwith this study, large heterogeneity in individual
metabolic patterns is found.The frequencyof theC9orf72mu-
tation in our cohort was very similar to that previously re-
ported series of patients with ALS (20%-50% of familial ALS
and 4%-10% of sporadic ALS).20,41
We found that perirolandic and prefrontal hypometabo-
lism is a sensitivemarkerofALS.C9orf72-positivepatientshad
a similar pattern, but the involvement of the posterior cingu-
late, thalamus, and prefrontal cortex was on average slightly
more severe. Similar affected areas were observed in a study
with diffusion-tensor MRI.42
Our findings are consistent with previous PET studies in
smaller samples, where metabolic abnormalities in the dor-
solateral prefrontal cortex and anteromedial cingulate cortex
were the most consistent findings. In C9orf72-negative ALS,
Figure 3. Most Discriminative Areas of Reduced GlucoseMetabolism in Amyotrophic Lateral Sclerosis (ALS) and Primary Lateral Sclerosis (PLS)
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Box-and-whisker plots of relative glucosemetabolism (normalized tomean gray
matter value) in volume of interest areas that are most discriminative between
healthy control cases, patients with ALS, and patients with PLS: prefrontal
(Brodmann Area [BA]9), motor cortex (BA4), anterior cingulate (BA 24,32), and
thalamus. L indicates left; PMA, progressive muscular atrophy; R, right.
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extramotor involvement has been studied before and consis-
tently reported,24,25 although not all studies found resting-
state hypometabolism or hypoperfusion.43
As was previously reported by Cistaro et al,32 relative hy-
permetabolism in the posterior areas, including the cerebel-
lum, occipital cortex, brain stem, andmesial temporal, is also
seen. Although this can purely be due to the relative normal-
ization procedure used, it has been suggested that this pat-
tern could reflect true hypermetabolism and ameasure of as-
trocytosis ormicroglial activation in theseareas.Thisquestion
of true hypermetabolism should be addressed by absolute re-
gional cerebralmetabolic ratesofglucosemeasurements toen-
able definite conclusions. In the same study, hypermetabo-
lism in the upper brain stem was particularly described in
spinal-onset forms only, but this was not confirmed in our
study, where both patients with spinal and bulbar onset ALS
showed completely similar patterns of hypometabolism (data
not shown).
The correlation between theALS-FRS scores andprefron-
tal hypometabolism is congruentwithprevious reports show-
ing that executive impairment is related to overall function-
ingof patients. LowerALS-FRS scores are also associatedwith
poorer prognosis.6 Extensive hypometabolism in the frontal
or temporal lobes was associated with shorter survival after
correction for other known prognostic factors. This is in line
withotherstudiesshowinganegativecorrelationbetweencon-
Figure 5. Survival Plots of PatientsWith Amyotrophic Lateral Sclerosis (ALS)With andWithout Extensive Frontotemporal Hypometabolism
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factor. A, Kaplan-Meier survival plots of patients with ALS with (n = 7) vs
without (n = 63) extensive frontotemporal hypometabolism (P < .001). B,
Kaplan-Meier survival plots of patients with ALS with (C9orf72+, n = 11) or
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A, Feature weights of the classifier for ALS vs healthy control cases projected
onto a normalized structural magnetic resonance image in Montreal
Neurological Institute space. The scale of the feature weights represents how
much a voxel contributes. The scale was normalized so that the sum of all
weights is 1. Only voxels with a weight of more than 0.002 in absolute value are
shown. Clusters indicate areas with high discriminative impact based on relative
hypometabolism (yellow-red) and relative hypermetabolism (blue). B, Plots of
distance to the classifier for healthy control cases (green) vs patients with ALS
(C9orf72 positive and C9orf72 negative grouped together) using a
leave-one-out approach.
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comitant frontotemporal dementia or cognitive or behavioral
impairment and survival.30,31
From a clinical point of view, this study has shown that,
althoughdeviations fromnormality are relativelymodest and
somevariability exists, thepatternof affection inpatientswith
ALS and those with PLS does allow for an accurate discrimi-
nationwithhealthy control cases, on aquantitative basis, and
evenbetweenpatientswithPLS andALS, albeitwith lower ac-
curacy andonly tested in a limited groupof patientswithPLS.
Thediscriminationof patientswithALSusingFDG-PET could
bean important additional tool inearlydiagnosesofnewcases
and in the assessment of diseaseprognosis. Andboth theVOI-
andSVM-basedanalysesperformed in this group remain tobe
validated in a novel prospective cohort of patients.
Our findings also support thenotion that PLS is part of the
widerMNDspectrum.The corollary is that themodifying fac-
tors (genetic and environmental) that account for the de-
layed progression of disease in patients with PLS, and which
are not clearly reflected bymajormetabolic differences as re-
sulting from this study, remain to be discovered.
A number of limitations of the study need to be men-
tioned. First, although routine MRI was performed in all pa-
tients, we did not apply a volume correction on the FDG-PET
of theparticipants.Atrophyhasbeendescribed inpatientswith
ALS,44-47butas formostpatients,novolumetricMRIdatawere
available; no partial volume correction was possible in this
dataset. This does not diminish the validity of the results and
their indicationofdiscriminatorypower in the functionalmeta-
bolic information, which is ameasure of implicit cellularme-
tabolism andmacroscopic atrophy effects.
Second,wedidnotassess the issueof laterality,whichmay
havecausedsomelevellingoutof information inpossible larger
deviations. Inmostpatients,however, relatively symmetric ce-
rebral cortical involvement seems to be the rule, and in pre-
vious studies, left-right (metabolic or perfusion) asymmetry
has not been regarded as a feature of ALS. Third, we did not
perform extensive cognitive testing in our patients. There-
fore, we cannot correlate the FDG-PET findings to cognitive
disability. Previous studieshave shownthatpatientswith cog-
nitive or behavioral impairment have a worse prognosis.2,31
HowFDG-PET findings relate to cognitive testing requires ad-
ditional study to further elucidate the mechanism by which
frontotemporalhypometabolismisassociatedwithworseprog-
nosis as was found here.
Fourth, theaccuracyof theclassificationanalysiswasbased
ona relatively small, butwell-defined, control groupof 20 sex-
and age-matched participants. Enlargement of the control
groupmayincreaseoverallperformanceof thetechnique.Fifth,
we have not defined a subset of patients and control cases as
a training set onwhich subsequent cases could be evaluated,
butwehaveused the leave-one-out technique to estimate fu-
ture applicability in novel clinical samples. Whereas this is a
necessary correction to establish robustness of classification
accuracy, future studies in novel patient groups with clinical
follow-upareneeded to fully validate the current findings. Fi-
nally, the clinical diagnosis of ALS was used as the gold stan-
dard for diagnosis and comparedwith a single FDG-PET scan.
We did not collect longitudinal FDG-PET data, perform FDG-
PET around the time of symptomonset before a clinical diag-
nosis of ALS wasmade, nor assess the specificity of the FDG-
PET changes to discriminate ALS from ALSmimics.
Conclusions
This study shows the promise on the individual patient level
ofaneffectivemetabolicPETmarker thathasvalue inearlyand
differential diagnosis in ALS and characterization of C9orf72-
positive ALS. It also holds prognostic information, with fron-
totemporal metabolic decrease related to poorer survival.
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